Cellular immunologic parameters related to age, gender, and stage in lung cancer patients

Lung Cancer

Volumn 28, Issue 2, 2000, Pages 139-145

  Nakamura, Haruhiko ^a   Kawasaki, Norihito ^a   Hagiwara, Masaru ^a   Saito, Makoto ^a   Konaka, Chimori ^a   Kato, Harubumi ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

HLA DR; Immune parameter; Lung cancer; Lymphocyte subsets; NK cell activity; Tumor immunity

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CANCER RISK; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ANTIGENS, CD4; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0034194129     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00133-6     Document Type: Article

References (35)

1. Wanebo J.H., Rao J., Miyazawa N., Martini N., Middeleman P.M., Oettgen F.H. et al. Immune reactivity in primary carcinoma of the lung and its relation to prognosis. J. Thorac. Cardiovasc. Surg. 72:1976;339-350.
2. Watanabe Y., Shimizu J., Hashizume Y., Tsunamura Y., Yamada T., Iwa T. et al. Immune reactivity in bronchogenic carcinoma and its relation to 5-year survival rates. J. Surg. Oncol. 45:1990;103-109.
3. Studonicka M., Wirnsberger R., Neumann M., Pokieser L., Angerler J. Peripheral blood lymphocyte subsets and survival in small-cell lung cancer. Chest. 105:1994;1673-1678.
4. Cannon B.G., Dean H.J., Herberman B.R., Perlin E., Reid J., Miller C. et al. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int. J. Cancer. 25:1980;9-17.
5. Dalbow H.M., Concannon P.J., Eng P.C., Weil S.C., Conway J., Narayanan Nambisan T.P. Lymphocyte mitogen stimulation studies for patients with lung cancer: evaluation of prognostic significance of preirradiation therapy studies. J. Lab. Clin. Med. 90:1977;295-302.
6. Mekori T., Shulamith S., Robinson E. Suppression of the mitogenic response to phytohemagglutinin in malignant neoplasia: correlation with clinical stage and therapy. Int. J. Natl. Cancer Inst. 52:1974;9-12.
7. Braeman J., Deeley J.P. The lymphocyte response and prognosis in cancer of the lung. Br. J. Radiol. 48:1975;668-669.
8. Mountain C.F., Dresler C.M. Regional lymph node classification for lung cancer staging. Chest. 111:1997;1718-1723.
9. Tamm A., Schmidt E.R. The binding epitopes of human CD16(FcgRIII) monoclonal antibodies. J. Immunol. 157:1996;1576-1581.
10. van de Winkel G.J.J., Capel J.A.P. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today. 14:1993;215-221.
11. Mascart-Lemone F., Delespesse G., Servais G., Kunstler M. Characterization of immunoregulatory T lymphocytes during ageing by monoclonal antibodies. Clin. Exp. Immunol. 48:1982;148-154.
12. Traill N.K., Schönitzer D., Jürgens G., Böck G., Pfeilshifter R., Hilchembach M. et al. Age-related changes in lymphocyte subset proportions, surface differentiation antigen density and plasma membrane fluidity: application of the Eurage Senieur protocol admission criteria. Mech. Ageing Dev. 33:1985;39-66.
13. Patricia K.K., Fineberg S.N., Freeman S.K., Redmond L.N., Charland C. Reference ranges for lymphocyte subsets in pediatric patients. Am. J. Clin. Pathol. 100:1993;111-115.
14. Lee B.W., Yap H.K., Chew F.T., Quah T.C., Prabhakaran K., Chan S.H.G. et al. Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. Cytometry. 26:1996;8-15.
15. Babcock F.G., Taylor F.A., Hynd A.B., Sramkoski R.M., Alexander J.W. Flow cytometric analysis of lymphocyte subset phenotypes comparing normal children and adults. Diag. Clin. Immunol. 5:1987;175-179.
16. Moretta L., Webb S.R., Grossi C.E., Lydyard P.M., Cooper M.D. Functional analysis of two human T-cell subpopulations, help and seppression of B-cell responses by T cells bearing receptors for IgM or IgG. J. Exp. Med. 146:1977;184-200.
17. McNerlan S.E., Rea I.M., Alexander H.D., Morris T.C.M. Changes in natural killer cells, the CD57CD8 subset, and related cytokines in healthy aging. J. Clin. Immunol. 18:1998;31-37.
18. Amigirena S., Lanker D., Briken V., Gapin L., Viguier M., Bonnerot C. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J. Exp. Med. 187:1998;505-515.
19. + T-cell line express functional CD64 (FcgRI), CD32 (FcgRII), and CD16 (FcgRIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes. Immunol 1997;90:109-14.
20. Galatiuc C., Gherman M., Metes D., Sulica A., DeLeo A., Whiteside L.W. et al. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies. Cell. Immunol. 163:1995;167-177.
21. de Haas M., Koene H.R., Kleijer M., de Vries E., Simsek S., van Tol J.D.M. et al. A triallelic Fcg receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcgRIIIa. J. Immunol. 156:1996;2948-2955.
22. Unkeless J.C., Shen Z., Lin C.W., DeBeus E. Function of human FcγRIIIA and FcγRIIIB. Sem. Immunol. 7:1995;37-44.
23. Miller K.L., Duchemin A.M., Anderson C.L. A novel role for the Fc receptor g subunit: enhancement of FcγR ligand affinity. J. Exp. Med. 183:1996;2227-2233.
24. Kimura M. Effect of perorally administered BCG on recurrent breast cancer. J. Surg. Oncol. 20:1982;65-69.
25. Ran M., Teillaud J.L., Friedman W.H., Frenkel H., Halachimi E., Katz B. et al. Increased expression of Fcγ receptor in cancer patients and tumor bearing mice. Mol. Immunol. 25:1988;1159-1167.
26. Johnson J.D., Houchens D.P., Kluwe W.M., Craig D.K., Fisher G.L. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: a review. Crit. Rev. Toxicol. 20:1990;369-395.
27. Barnes E.W., Farmer A., Penhale W.J., Irvine W.J., Roscoe P., Horne N.W. Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer. 36:1975;187-193.
28. Holmes E.C., Golub S.H. Immunologic defects in lung cancer patients. J. Thorac. Cardiovasc. Surg. 71:1976;77-84.
29. Arista M.C., Callopoli A., De Franceschi L., Santini A., Schiratti M., Conti L. et al. Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma. Dis. Colon Rectum. (Suppl). 37:1994;S30-S34.
30. Morton B.A., Ramey W.G., Paderon H., Miller R.E. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res. 46:1986;2121-2126.
31. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int. J. Cancer. 61:1995;470-474.
32. Zeromski J., Pietrzak J., Szmeja Z., Jezewska E., Gorny M.K., Kruk-Zagajewska A. Evaluation of phenotype of mononuclear host cells isolated from primary tumour and peripheral blood of patients with laryngeal carcinoma. Acta. Otolaryngol. 105:1988;149-154.
33. +) T-lymphocyte subsets in early epithelial ovarian cancer and malignant ovarian germ cell tumors. Gynecol. Oncol. 58:1995;362-367.
34. + surface phenotype in invaded lymph nodes from patients with solid tumors. Int. J. Nat. Cancer Inst. 77:1986;637-641.
35. Kikuchi Y., Iwano I., Kita T., Miyauchi M., Kuki E., Oomori K. et al. Changes of lymphocyte subsets in peripheral blood before and after operation of patients with advanced ovarian carcinoma. J. Cancer Res. Clin. Oncol. 116:1990;283-287.